Search research articles
Contact Us
Filters
Showing results (1-10 of 104) with videos related to
Page
of 11
Sort By:
Current Opinion in Investigational Drugs (London, England : 2000)
|
December 17, 2004
HepeX-C (XTL Biopharmaceuticals)
Guglielmo Borgia
Idrugs : the Investigational Drugs Journal
|
June 16, 2004
Specific immunoglobulin against HCV: new perspectives
Guglielmo Borgia
The Lancet. Infectious Diseases
|
April 13, 2015
A pill a day keeps HCV away
Ivan Gentile, Guglielmo Borgia
International Journal of Women'S Health
|
June 27, 2014
Vertical transmission of hepatitis B virus: challenges and solutions
Ivan Gentile, Guglielmo Borgia
Journal of Hepatology
|
March 30, 2010
Surrogate endpoints and non-inferiority trials in chronic viral hepatitis
Ivan Gentile, Guglielmo Borgia
Expert Review of Anti-Infective Therapy
|
August 11, 2010
Development and progression of gastroesophageal varices in patients with chronic hepatitis C
Ivan Gentile, Guglielmo Borgia
Evidence-Based Medicine
|
July 17, 2014
Ledipasvir/Sofosbuvir administration achieves very high rate of viral clearance in patients with HCV genotype 1 infection without cirrhosis, regardless of ribavirin co-administration or length of treatment
Ivan Gentile, Guglielmo Borgia
Hepatology (Baltimore, Md.)
|
October 16, 2004
Immune system homeostasis during acute hepatitis C: viral escape or T-cell regulation?
Alessandro Perrella, Guglielmo Borgia, Oreste Perrella
BMC Infectious Diseases
|
March 9, 2010
Is the drug-induced hypersensitivity syndrome (DIHS) due to human herpesvirus 6 infection or to allergy-mediated viral reactivation? Report of a case and literature review
Ivan Gentile, Maria Talamo, Guglielmo Borgia
Translational Gastroenterology and Hepatology
|
December 22, 2017
Direct acting antiviral agents and hepatocellular carcinoma development: don't take it for granted
Antonio Riccardo Buonomo, Ivan Gentile, Guglielmo Borgia
Page
of 11
Search research articles
Search
Showing results (1-10 of 104) with videos related to
Sort By:
Page
of 11
Current Opinion in Investigational Drugs (London, England : 2000)
|
December 17, 2004
HepeX-C (XTL Biopharmaceuticals)
Guglielmo Borgia
Idrugs : the Investigational Drugs Journal
|
June 16, 2004
Specific immunoglobulin against HCV: new perspectives
Guglielmo Borgia
The Lancet. Infectious Diseases
|
April 13, 2015
A pill a day keeps HCV away
Ivan Gentile, Guglielmo Borgia
International Journal of Women'S Health
|
June 27, 2014
Vertical transmission of hepatitis B virus: challenges and solutions
Ivan Gentile, Guglielmo Borgia
Journal of Hepatology
|
March 30, 2010
Surrogate endpoints and non-inferiority trials in chronic viral hepatitis
Ivan Gentile, Guglielmo Borgia
Expert Review of Anti-Infective Therapy
|
August 11, 2010
Development and progression of gastroesophageal varices in patients with chronic hepatitis C
Ivan Gentile, Guglielmo Borgia
Evidence-Based Medicine
|
July 17, 2014
Ledipasvir/Sofosbuvir administration achieves very high rate of viral clearance in patients with HCV genotype 1 infection without cirrhosis, regardless of ribavirin co-administration or length of treatment
Ivan Gentile, Guglielmo Borgia
Hepatology (Baltimore, Md.)
|
October 16, 2004
Immune system homeostasis during acute hepatitis C: viral escape or T-cell regulation?
Alessandro Perrella, Guglielmo Borgia, Oreste Perrella
BMC Infectious Diseases
|
March 9, 2010
Is the drug-induced hypersensitivity syndrome (DIHS) due to human herpesvirus 6 infection or to allergy-mediated viral reactivation? Report of a case and literature review
Ivan Gentile, Maria Talamo, Guglielmo Borgia
Translational Gastroenterology and Hepatology
|
December 22, 2017
Direct acting antiviral agents and hepatocellular carcinoma development: don't take it for granted
Antonio Riccardo Buonomo, Ivan Gentile, Guglielmo Borgia
Page
of 11